These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 37006073

  • 1. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India.
    Gupta PK, Rastogi N, Maria Das KJ, Kumar S.
    J Cancer Res Ther; 2023; 19(2):382-388. PubMed ID: 37006073
    [Abstract] [Full Text] [Related]

  • 2. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
    Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.
    Radiat Oncol; 2012 Jul 06; 7():105. PubMed ID: 22770471
    [Abstract] [Full Text] [Related]

  • 3. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
    Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M, Hunt M.
    Int J Radiat Oncol Biol Phys; 2012 Sep 01; 84(1):125-9. PubMed ID: 22330997
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
    Nakamura K, Mizowaki T, Inokuchi H, Ikeda I, Inoue T, Kamba T, Ogawa O, Hiraoka M.
    Int J Clin Oncol; 2018 Feb 01; 23(1):158-164. PubMed ID: 28756594
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
    Rudat V, Nour A, Hammoud M, Alaradi A, Mohammed A.
    Strahlenther Onkol; 2016 Feb 01; 192(2):109-17. PubMed ID: 26545764
    [Abstract] [Full Text] [Related]

  • 9. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
    Zapatero A, Roch M, Büchser D, Castro P, Fernández-Banda L, Pozo G, Liñán O, Martin de Vidales C, Cruz-Conde A, García-Vicente F.
    Clin Transl Oncol; 2017 Sep 01; 19(9):1161-1167. PubMed ID: 28374321
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
    Marina O, Gustafson GS, Kestin LL, Brabbins DS, Chen PY, Ye H, Martinez AA, Ghilezan MI, Wallace M, Krauss DJ.
    Brachytherapy; 2014 Sep 01; 13(1):59-67. PubMed ID: 23871661
    [Abstract] [Full Text] [Related]

  • 14. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.
    Sveistrup J, af Rosenschöld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, Engelholm SA.
    Radiat Oncol; 2014 Feb 04; 9():44. PubMed ID: 24495815
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
    Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, Scrase C, Parker C, Khoo V, Dean J, Mayles H, Mayles P, Thomas S, Naismith O, Baker A, Mossop H, Cruickshank C, Hall E, Dearnaley D, CHHiP Investigators.
    Radiother Oncol; 2020 Jan 04; 142():62-71. PubMed ID: 31767473
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
    Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.
    Int J Radiat Oncol Biol Phys; 2012 Jan 01; 82(1):184-90. PubMed ID: 21163590
    [Abstract] [Full Text] [Related]

  • 19. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T, Jorcano S, Escudé L, Linero D, Rouzaud M, Dubouloz A, Miralbell R.
    Clin Oncol (R Coll Radiol); 2014 Jun 01; 26(6):316-22. PubMed ID: 24667210
    [Abstract] [Full Text] [Related]

  • 20. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
    Bayley A, Rosewall T, Craig T, Bristow R, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Warde P, Catton C.
    Int J Radiat Oncol Biol Phys; 2010 Jun 01; 77(2):477-83. PubMed ID: 19733014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.